Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH Family Wildtype”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Testing effectiveness (Phase 2)Looking for participantsNCT05664464
What this trial is testing

Glutamate Inhibitors in Glioblastoma

Who this might be right for
Glioblastoma
University of Zurich 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT03897491
What this trial is testing

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

Who this might be right for
Glioblastoma
photonamic GmbH & Co. KG 20
Testing effectiveness (Phase 2)Ended earlyNCT05267106
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Who this might be right for
GlioblastomaAdult-type Diffuse Gliomas
Incyte Corporation 83
Testing effectiveness (Phase 2)Ended earlyNCT03022578
What this trial is testing

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Who this might be right for
IDH Family WildtypeRecurrent Anaplastic AstrocytomaRecurrent Glioblastoma
M.D. Anderson Cancer Center 7
Very early researchLooking for participantsNCT06552260
What this trial is testing

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Who this might be right for
GlioblastomaRecurrent GlioblastomaBrain Tumor
Ugonma Chukwueke 27
Not applicableLooking for participantsNCT06964815
What this trial is testing

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Who this might be right for
GlioblastomaIDH Wild-type and STAT3-positive Glioblastoma
Istituto Oncologico Veneto IRCCS 110
Testing effectiveness (Phase 2)UnknownNCT04614493
What this trial is testing

Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.

Who this might be right for
Initial Radiological Diagnosis Eligible for Tumor ResectionInitial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide
Assistance Publique - Hôpitaux de Paris 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06258018
What this trial is testing

Niraparib and Temozolomide in Patients Glioblastoma

Who this might be right for
Glioma, Malignant
Armando Santoro, MD 86
Early research (Phase 1)Not Yet RecruitingNCT07185880
What this trial is testing

The Safety and Tolerability of MT-125 in GBM Patients

Who this might be right for
Glioblastoma (GBM)
Myosin Therapeutics Inc. 36
Very early researchUnknownNCT02766270
What this trial is testing

CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas

Who this might be right for
Grade II/III Glioma
Beijing Tiantan Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05871021
What this trial is testing

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

Who this might be right for
Glioblastoma
University Hospital Tuebingen 146
Early research (Phase 1)Looking for participantsNCT07223034
What this trial is testing

177Lu-PSMA-617 in People With Gliomas

Who this might be right for
GliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtype+3 more
Memorial Sloan Kettering Cancer Center 20
Not applicableNot Yet RecruitingNCT06368934
What this trial is testing

Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma

Who this might be right for
GliomaGlioblastoma
Huashan Hospital 326
Testing effectiveness (Phase 2)Study completedNCT03234595
What this trial is testing

A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

Who this might be right for
Recurrent GBM
Everfront Biotech Co., Ltd. 22
Early research (Phase 1)Study completedNCT06095375
What this trial is testing

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients

Who this might be right for
Glioblastoma, IDH-wildtypeMGMT-Methylated Glioblastoma
Istituto Oncologico Veneto IRCCS 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT04910022
What this trial is testing

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Who this might be right for
GlioblastomaDiffuse Glioma
Nerviano Medical Sciences 150
Testing effectiveness (Phase 2)WithdrawnNCT05218408
What this trial is testing

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Who this might be right for
Astrocytoma, Grade IVGlioblastomaGiant Cell Glioblastoma+1 more
Celularity Incorporated
Large-scale testing (Phase 3)Looking for participantsNCT03970447
What this trial is testing

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Who this might be right for
Glioblastoma
Global Coalition for Adaptive Research 1,280
Testing effectiveness (Phase 2)Looking for participantsNCT05859334
What this trial is testing

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Who this might be right for
Recurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
National Cancer Institute (NCI) 35